Summary
Vertex Pharmaceuticals Inc. reported a net loss of $176.1 million for the first quarter of 2011, an increase from $165.3 million in the same period of the previous year. This widening loss was driven by a significant increase in R&D and SG&A expenses, largely in preparation for the potential launch of its hepatitis C drug, telaprevir. Despite the increased expenses and net loss, total revenues surged by 228% to $73.7 million, primarily due to a $50 million milestone payment from Janssen Pharmaceutica for telaprevir's marketing authorization application acceptance in Europe. The company's cash, cash equivalents, and marketable securities stood at $823.5 million as of March 31, 2011. While this represents a decrease from the prior quarter, management believes it is sufficient to fund operations for at least the next twelve months. Vertex is on track for a potential US launch of telaprevir in mid-2011, contingent on FDA approval, which has an anticipated decision date of May 23, 2011. Additionally, positive Phase 3 results for the cystic fibrosis drug candidate VX-770 were announced, with an NDA submission expected in the second half of 2011. Investors should closely monitor the FDA's decision on telaprevir and the progress of VX-770 as key drivers of future financial performance.
Financial Highlights
48 data points| Revenue | $73.66M |
| Cost of Revenue | $0 |
| Gross Profit | $73.66M |
| R&D Expenses | $158.61M |
| SG&A Expenses | $71.52M |
| Operating Expenses | $233.56M |
| Operating Income | -$159.90M |
| Interest Expense | $12.00M |
| Net Income | -$176.10M |
| EPS (Basic) | $-0.87 |
| EPS (Diluted) | $-0.87 |
| Shares Outstanding (Basic) | 202.33M |
| Shares Outstanding (Diluted) | 202.33M |
Key Highlights
- 1Net loss increased to $176.1 million for Q1 2011 from $165.3 million in Q1 2010.
- 2Total revenues increased significantly by 228% to $73.7 million in Q1 2011, driven by a $50 million milestone payment from Janssen for telaprevir.
- 3Research and Development (R&D) expenses rose by 11% to $158.6 million, reflecting continued investment in drug development programs, particularly telaprevir and VX-770.
- 4Sales, General, and Administrative (SG&A) expenses more than doubled, increasing by 101% to $71.5 million, due to expansion of the commercial team in anticipation of telaprevir launch.
- 5Cash, cash equivalents, and marketable securities totaled $823.5 million at the end of Q1 2011, providing a solid liquidity position.
- 6Vertex received a unanimous recommendation from an FDA advisory committee for the approval of telaprevir, with a target decision date of May 23, 2011.
- 7Positive Phase 3 data for VX-770 (cystic fibrosis drug) was reported, with an NDA submission planned for the second half of 2011.